No pain data yet from Vertex, and sky high deal expectations at JPM 2024
Today's Readout newsletter: Sky high deal expectations going into JPM 2024, no pain data yet from Vertex, is JPM good for the XBI and other biotech news updates.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Greetings from JPM Week 2024! We’re coming to you live from San Francisco, where the industry’s biggest annual convocation is about to kick off — this time, without any substantive chatter about relocation to warmer, drier climes. And why would we leave SF? That yellow orb you see in the sky? It’s the sun! Our morning newsletter has switched to an afternoon format so that our team of STAT reporters on the ground — Allison DeAngelis, Damian Garde, Adam Feuerstein, Matthew Herper, Tara Bannow, Mohana Ravindranath, and Angus Chen — can bring you all the news, analysis, and cocktail party gossip. Let’s do this!
What's Your Reaction?
